


Case Two

- 35 year old G2P2 LMP 9-30-20. No history of abnormal pap. Current pap: Unsatisfactory HPV Negative.
- What is the next step?

1. Repeat cytology only in 2-4 months.
2. Repeat cotest 2-4 months
3. Repeat cotest ASAP



Clinical Scenario #2

Clinical Situation

- 35 yo Unsat cytology, HPV-
- Management of routine screening results
- Choosing Cytology "None" is not equivalent to an Unsatisfactory result.
- Unable to apply results in app



Case Three


49 yo G3 P3 in today for annual exam. She is in pap follow up due to adenocarcinoma in situ which resulted in a complete hysterectomy 10 years ago; all cotest have been negative since. How will you manage this patient?

- A. Pelvic exam but do not obtain pap since her hysterectomy has been 10 years
- B. Cotest q3 years for at least 25 years
- C. Cytology every year for at least 25 years



Case Three


management of AIS. This management algorithm was developed by the Society of Gynecologic Oncology and endorsed by the ASCCP Risk-Based Management Consensus process.



Clinical Scenario #3

Clinical Situation

- 49 yo NILM-, prior AIS
- Follow-up after treatment



Clinical Scenario #3

Current Testing

- NILM, HPV negative

Clinical Scenario #3

Prior Testing and Treated Histology

- Multiple Negative Cotests
- AIS

Clinical Scenario #3

Confirmation

- Cotest with negative HPV and normal cytology
- Treatment for histologic AIS

Clinical Scenario #3

Recommendation

- Cotest annually x 3 yrs
- Then q3yrs x at least 25 years

Case Four

- 37 year old G3 P3 in for annual exam. Last cotest 5 years ago with results NIL/ HPV negative and no history of abnormal paps. Cotest today returns with results LSIL HPV +. What is your plan of care for this patient?
 - Refer for colposcopy
 - Repeat cotest in one year



TABLE 1B
Incidence and 5-Year Rates of CIN 3+ After a Prior HPV-Negative Screen Documented in the Medical Record

Screen	Current HPV result	Current cytology	n	%	CIN 3+ incidence	5-yr rate	5-yr rate, 95% CI	Management	Recommendation confidence score, %
HPV-negative	HPV-negative	Normal	163,151	94.9	149	0.09	0.09	2-yr follow-up	100
HPV-negative	HPV-negative	ASC-US	14,172	7.4	41	0.29	0.29	2-yr follow-up	100
HPV-negative	HPV-negative	LSIL	1,010	0.6	16	1.6	1.6	Colposcopy	91
HPV-negative	HPV-negative	ASC-US	1,010	0.6	16	1.6	1.6	Colposcopy	98
HPV-negative	HPV-negative	LSIL	1,010	0.6	16	1.6	1.6	Colposcopy	98
HPV-negative	HPV-positive	Normal	163,151	94.9	223	0.14	0.14	2-yr follow-up	100
HPV-negative	HPV-positive	ASC-US	14,172	7.4	141	1.0	1.0	2-yr follow-up	100
HPV-negative	HPV-positive	LSIL	1,010	0.6	14	1.4	1.4	Colposcopy	91
HPV-negative	HPV-positive	ASC-US	1,010	0.6	14	1.4	1.4	Colposcopy	98
HPV-negative	HPV-positive	LSIL	1,010	0.6	14	1.4	1.4	Colposcopy/treatment	100
		Total	1,010,111	100	478	0.28			

HPV vaccination confidence score is not used for search in 100%.

5-yr rate: 95% confidence interval.

We can be managed by 100%.

After HPV-negative screening, women with LSIL, ASC-US, or HPV-positive results should be managed according to the 2012 guideline. This table shows the 5-year rates of CIN 3+ after a prior HPV-negative screen documented in the medical record. The table shows the 5-year rates of CIN 3+ after a prior HPV-negative screen documented in the medical record. The table shows the 5-year rates of CIN 3+ after a prior HPV-negative screen documented in the medical record.

The first column indicates the current HPV test result before the current visit was negative. The second and third columns represent current screening results. The fourth column shows the test sample size by each category and each screening result as a percentage of total screened women. The fifth column shows the 5-year rates of CIN 3+ by screening result. The sixth column shows the 5-year rates of CIN 3+ by screening result. The seventh column shows the 5-year rates of CIN 3+ by screening result. The eighth column shows the 5-year rates of CIN 3+ by screening result. The ninth column shows the 5-year rates of CIN 3+ by screening result. The tenth column shows the 5-year rates of CIN 3+ by screening result.

The 2012 guideline for the management of women with HPV test results: HPV-negative ASC-US/LSIL, possibly requires HPV test and/or management to be followed up in 1 year rather than immediately referred to colposcopy.

HPV-negative, ASC-US, possibly requires HPV management.

HPV-negative, LSIL, is included from the need to avoid colposcopy.

JOURNAL OF LOWER GENITAL TRACT DISEASE

Documented prior negative HPV (KPNC)

HPV	Pap	Immediate risk (%) after prior HPV neg	Immediate risk (%) no prior HPV test
Pos	HSIL+	32.28	48.86
Pos	ASC-H	13.56	25.73
Neg	HSIL+	13.80	25.21
Pos	LSIL	2.10	4.27
Pos	ASC-US	2.03	4.45
Pos	NILM	0.74	2.13
Neg	LSIL	0.44	1.05
Neg	ASC-US	0.014	0.04
Neg	NILM	0.001	0.002

Egemen D et al. J Low Genit Tract Dis 2020;24(2):132-143.

Clinical Scenario #4

Clinical Situation and Current Testing

- 37 yo LSIL+, prior NILM-
- Management of routine screening results

Clinical Scenario #4

Previous Testing

- NILM, HPV negative

Clinical Scenario #4


Confirmation

- Review current and prior results

Clinical Scenario #4

Recommendation

- 1- year follow-up
- Risk bar 3.78%
- Less than 4% indicating colposcopy referral



Case Five

- 49 year old G1 P1 LMP 10/20/2020 with history of BTL in for CDA
- She is currently in pap follow up due to LSIL one year ago and was noncompliant with recommendations
- Most recent pap returned HSIL and colposcopy ECC CIN 3 with recommendations for LEEP
- The LEEP was completed



Case Five - Short term follow up after LEEP

- LEEP confirmed HSIL (CIN 3) diagnosis; margins of resection are free of high grade dysplasia.
- **What is the next steps in follow up?**
- A- Cotest one year
- B- Cytology and ECC in 4-6 months
- C- Cotest in 6 months






Figure 7: Management of Histologic HSIL (CIN2 or CIN3 or Not Further Specified)*



Clinical Scenario #5

Clinical Situation


- 49 yo LEEP, Bx HSIL, prior HSIL and LSIL
- Evaluation of a colposcopic biopsy



Clinical Scenario #5

Colposcopy Histology


- HSIL (CIN 3)



Clinical Scenario #5

Confirmation

- Review information entered



Clinical Scenario #5

Recommendation

- Treatment
 - Cotesting at 6 months
- Algorithm given




Case Five

- The short term follow up post LEEP 6 month cotest was NIL/HPV-
- How will you counsel this 49 year old with history of LEEP CIN 2 with free margins on her long term plan of care?
 - A. Cotesting annual x 3 for 3 consecutive negative test then q3years for at least 25 year
 - B. Cotesting annual x 2 for 2 consecutive negative test then q3years for at least 25 year
 - C. Since she is 49 she will only need cotest q3years until she reaches age 65

Clinical Scenario #5

Clinical Situation


- 49 yo NILM-, LEEP, Bx HSIL, prior HSIL, LSIL
- Follow-up after Treatment



Clinical Scenario #5

Current Testing and Treated Histology

- NILM, HPV negative
6 mo Cotest s/p LEEP
- HSIL (CIN 3)



Clinical Scenario #5

Confirmation

- Review Current Results and Treatment entered



Clinical Scenario #5

Recommendation

- 1 year Follow-up
- Review Algorithm

